6809
First Published: Sun, Jan 05 2014. 07 17 PM IST

GlaxoSmithKline seeks FIPB nod to hike stake in Indian arm

Singapore subsidiary of the UK-based pharma firm will buy 24.33% stake or 2.06 crore shares through an open offer
E-mailPrint
PTI Mail Me
GlaxoSmithKline seeks FIPB nod to hike stake in Indian arm
The GlaxoSmithKline proposal will come up before the meeting of the, headed by economic affairs secretary Arvind Mayaram. Photo: Hemant Mishra/Mint
New Delhi: UK-based drug major GlaxoSmithKline Plc is knocking at the FIPB’s doors to raise stake in its India arm by acquiring an additional 24.33% for around Rs.6,400 crore.
The proposal will come up before the meeting of the Foreign Investment Promotion Board (FIPB), headed by economic affairs secretary Arvind Mayaram, on 10 January.
According to people in the know of the development, the Singapore subsidiary of the UK-based pharma firm will be buying 24.33% stake or 2.06 crore equity shares in GlaxoSmithKline through an open offer.
After purchase, the holding of the promoter group companies in the Indian subsidiary will go up to 75% from the current 50.67%. GlaxoSmithKline is already majority owned and controlled by the GSK Group.
“There the proposed transaction will not result in any change in control of the Indian arm,” people in the know told PTI. The acquisition would result in foreign exchange inflows of Rs.6,400 crore, they added.
Comment E-mail Print   0
First Published: Sun, Jan 05 2014. 07 17 PM IST
More Topics: GlaxoSmithKline | FIPB | Stake | India | Singapore |
blog comments powered by Disqus
  • Wed, Apr 16 2014. 06 11 PM
  • Wed, Apr 09 2014. 05 19 PM
ALSO READclose

Hobbiton, New Zealand | Down the hobbit hole

Subscribe |  Contact Us  |  mint Code  |  Privacy policy  |  Terms of Use  |  Advertising  |  Mint Apps  |  About HT Media  |  Jobs
Contact Us
Copyright © 2014 HT Media All Rights Reserved